{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:56:04Z","timestamp":1776416164584,"version":"3.51.2"},"reference-count":123,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ELPEN"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and provide appropriate care promptly to these patients. In addition, established and new drugs contribute to primary and secondary cardiovascular diseases prevention. This review focuses on the clinical manifestations, preventive strategies, and pharmaceutical management of cardiotoxicity in patients with hematologic malignancies undergoing anticancer drug therapy or hematopoietic stem cell transplantation.<\/jats:p>","DOI":"10.3390\/ph15081007","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T03:15:27Z","timestamp":1660706127000},"page":"1007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies"],"prefix":"10.3390","volume":"15","author":[{"given":"Anastasia Stella","family":"Perpinia","sequence":"first","affiliation":[{"name":"Department of Cardiology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-3488","authenticated-orcid":false,"given":"Nikolaos","family":"Kadoglou","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vardaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Gkortzolidis","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Karavidas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Marinakis","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrysostomi","family":"Papachrysostomou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Makaronis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charikleia","family":"Vlachou","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cG. Gennimatas\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Mantzourani","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, \u201cLaiko\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Konstantopoulos","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical School, National and Kapodistrian University of Athens, \u201cLaiko\u201d General Hospital, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. A Systematic Analysis for the Global Burden of Disease Study","volume":"4","author":"Fitzmaurice","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_4","first-page":"474","article-title":"Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations","volume":"70","author":"Luis","year":"2017","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Skitch, A., Mital, S., Mertens, L., Liu, P., Kantor, P., Grosse-Wortmann, L., Manlhiot, C., Greenberg, M., and Nathan, P.C. (2017). Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: A multi-centre observational study. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3505-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ejhf.1172","article-title":"Anthracycline-induced cardiomyopathy: Secrets and lies","volume":"20","author":"Farmakis","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and Management of Patients with Heart Disease and Cancer: Cardio-Oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Adhikari, A., Asdaq, S.M.B., Al Hawaj, M.A., Chakraborty, M., Thapa, G., Bhuyan, N.R., Imran, M., Alshammari, M.K., Alshehri, M.M., and Harshan, A.A. (2021). Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics. Pharmaceuticals, 14.","DOI":"10.3390\/ph14100970"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cjca.2016.01.027","article-title":"Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond","volume":"32","author":"Moudgil","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-020-00812-1","article-title":"Metabolic Aspects of Anthracycline Cardiotoxicity","volume":"22","author":"Russo","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated with Doxorubicin-Induced Cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2014.894187","article-title":"The more patients you treat, the more you cure: Managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma","volume":"56","author":"Zinzani","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","first-page":"47","article-title":"Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy","volume":"9","author":"Hamo","year":"2015","journal-title":"Clin. Med. Insights Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.blre.2015.11.001","article-title":"Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart\u2019s content","volume":"30","author":"Oliveira","year":"2016","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11936-018-0627-x","article-title":"Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment","volume":"20","author":"Spetz","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclo-phosphamide-induced cardiotoxicity: Old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1179546819866445","DOI":"10.1177\/1179546819866445","article-title":"Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin. Med. Insights Cardiol."},{"key":"ref_22","first-page":"1132","article-title":"Cardiotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_23","first-page":"280","article-title":"Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics. What Is the Evidence?","volume":"1","author":"Kamphuis","year":"2019","journal-title":"J. Am. Coll Cardiol. CardioOncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107552","DOI":"10.1016\/j.pharmthera.2020.107552","article-title":"An overview on anti-tubulin agents for the treatment of lymphoma patients","volume":"211","author":"Barreca","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753944719843435","article-title":"Cardiotoxicity due to targeted anticancer agents: A growing challenge","volume":"13","author":"Shah","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome\u2013Positive Leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular Complications of Cancer Chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary Arterial Hypertension in Patients Treated by Dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"84","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: Importance and management","volume":"34","author":"Suter","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.15171\/jrip.2017.04","article-title":"Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy","volume":"6","author":"Cheungpasitporn","year":"2016","journal-title":"J. Ren. Inj. Prev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"bcr2014208203","DOI":"10.1136\/bcr-2014-208203","article-title":"Rituximab-induced Takotsubo syndrome: More cardiotoxic than it appears?","volume":"2015","author":"Ng","year":"2015","journal-title":"BMJ Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1200\/JCO.2017.76.3920","article-title":"Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention","volume":"36","author":"Armenian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy- incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of American Hy-pertension (SHA)","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6616265","DOI":"10.1155\/2021\/6616265","article-title":"Assessment and Management of Cardiotoxicity in Hematologic Malignancies","volume":"2021","author":"Bojan","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11897-018-0400-1","article-title":"Prevention of Cardiotoxicities with Traditional and Novel Chemotherapeutic Agents","volume":"15","author":"Sharalaya","year":"2018","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11936-020-00867-1","article-title":"Cardiotoxicity of Contemporary Anticancer Immunotherapy","volume":"22","author":"Patel","year":"2020","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Khan, M., Maker, A., and Jain, S. (2021). The Evolution of Cancer Immunotherapy. Vaccines, 9.","DOI":"10.3390\/vaccines9060614"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric Antigen Receptor T-Cell Therapy\u2013Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-019-0774-6","article-title":"Cardiac Complications in the Adult Bone Marrow Transplant Patient","volume":"21","author":"Tuzovic","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11936-016-0447-9","article-title":"Cardiovascular Complications of Hematopoietic Stem Cell Transplantation","volume":"18","author":"Blaes","year":"2016","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: One size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11239-020-02344-9","article-title":"Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation Thrombosis and Thrombolysis","volume":"51","author":"Rotz","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtct.2020.11.007","article-title":"Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant","volume":"27","author":"Isidori","year":"2020","journal-title":"Transplant. Cell. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2015.127","article-title":"Arrhythmias in the setting of hematopoietic cell transplants","volume":"50","author":"Tonorezos","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ejh.13482","article-title":"Clinical prevalence and outcome of cardiovascular events in the first 100 days post allogeneic HSCT","volume":"106","author":"Alblooshi","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.beha.2008.02.002","article-title":"Vascular endothelium as \u201cnovel\u201d target of graft versus- host disease","volume":"21","author":"Tichelli","year":"2008","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e002843","DOI":"10.1161\/CIRCHEARTFAILURE.115.002843","article-title":"Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions","volume":"9","author":"Hamo","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.21873\/anticanres.15348","article-title":"Cardio-Oncology Preclinical Models: A Comprehensive Review","volume":"41","author":"Bouleftour","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of Cancer Therapy-Associated Car-diovascular Toxocity. A Scientific Statement From The American Heart Association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor\u2014Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.12688\/f1000research.15190.1","article-title":"Protecting the heart in cancer therapy","volume":"7","author":"Finet","year":"2018","journal-title":"F1000Research"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000455823","article-title":"Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview","volume":"62","author":"Menna","year":"2017","journal-title":"Chemotherapy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-019-0036-7","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: A consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardio-Oncology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"847012","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: Re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Futur. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.19.02856","article-title":"Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients with Acute Myeloid Leukemia: A Report From the Children\u2019s Oncology Group","volume":"38","author":"Getz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_67","first-page":"36","article-title":"Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia","volume":"7","author":"Vachhani","year":"2017","journal-title":"Leuk. Res. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphys.2018.00167","article-title":"Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40959-016-0010-6","article-title":"Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents","volume":"2","author":"Morbidelli","year":"2016","journal-title":"Cardio-Oncology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective Effect of Carvedilol on Adriamycin-Induced Left Ventricular Dysfunction in Children With Acute Lymphoblastic Leukemia","volume":"18","author":"Tolba","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","article-title":"Preventive role of carvedilol in adriamycin-induced cardiomyopathy","volume":"144","author":"Jhorawat","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","article-title":"Protective Effect of Carvedilol in Cardiomyopathy Caused by Anthracyclines in Patients Suffering from Breast Cancer and Lymphoma","volume":"9","author":"Salehi","year":"2011","journal-title":"Am. Heart Hosp. J. Winter"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Cardiac Imaging in Heart Failure Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients with Malignant Hemopathies. The OVERCOME Trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.amjcard.2018.08.039","article-title":"Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity","volume":"122","author":"Kheiri","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity\u2014a systematic review and meta-analysis of carvedilol","volume":"24","author":"Huang","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system\u2014from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","article-title":"Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy","volume":"17","author":"Janbabai","year":"2016","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"104","author":"Nakamae","year":"2005","journal-title":"Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction","volume":"2","author":"Piras","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"863314","DOI":"10.3389\/fcvm.2022.863314","article-title":"Novel Therapeutics for Anthracycline Induced Cardiotoxicity","volume":"9","author":"Vuong","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cjca.2014.11.020","article-title":"Chronic Statin Administration May Attenuate Early Anthracycline-Associated Declines in Left Ventricular Ejection Function","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11886-016-0731-z","article-title":"Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss","volume":"18","author":"Cardinale","year":"2016","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of High-Dose Chemotherapy\u2013Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: A multicenter randomized trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early Detection of Anthracycline Cardiotoxicity and Improvement with Heart Failure Therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril\u2013valsartan in cancer patients with heart failure","volume":"7","author":"Mitroi","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: Atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"Am. Coll. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"2","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.blre.2019.03.005","article-title":"Atrial fibrillation and cancer\u2014An unexplored field in cardiovascular oncology","volume":"35","author":"Chu","year":"2019","journal-title":"Blood Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ehjcvp\/pvaa037","article-title":"Identification of anticancer drugs associated with atrial fibrillation: Analysis of the WHO pharmacovigilance database","volume":"7","author":"Alexandre","year":"2021","journal-title":"Eur. Hear. J. Cardiovasc. Pharmacother."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kattelus, H., Kes\u00e4niemi, Y.A., Huikuri, H., and Ukkola, O. (2018). Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study). PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205454"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review","volume":"6","author":"Gilbert","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1080\/10428194.2018.1457149","article-title":"Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System","volume":"59","author":"Cheng","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area","volume":"34","author":"Mir","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.10.007","article-title":"Comparison of CHA2DS2-VASc, CHADS2 and HATCH scores for the prediction of new-onset atrial fibrillation in cancer patients: A nationwide cohort study of 760,339 study participants with competing risk analysis","volume":"266","author":"Hu","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_104","first-page":"066","article-title":"Predictors of Over-Anticoagulation in Warfarin Users in the UK General Population: A Nested Case\u2013Control Study in a Primary Health Care Database","volume":"119","author":"Gaist","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thrombo-embolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients with Cancer with Venous Thromboembolism: Results of a Randomized Tri-al (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"619650","DOI":"10.3389\/fcvm.2021.619650","article-title":"Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies","volume":"8","author":"Xu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global Longitudinal Strain and Cardiac Events in Patients with Immune Checkpoint Inhibitor-Related Myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccl.2019.07.008","article-title":"Cardiotoxicity of Immune Therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol. Clin."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","article-title":"Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease","volume":"74","author":"Desai","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_116","first-page":"343","article-title":"Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification","volume":"3","author":"Bergom","year":"2021","journal-title":"J. Am. Coll. Cardiol. CardioOncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00392-021-01809-y","article-title":"Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: From bench to bedside","volume":"110","author":"Varga","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1089\/jayao.2017.0075","article-title":"The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial","volume":"8","author":"Marlatt","year":"2019","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14656566.2018.1446080","article-title":"Treating cardiovascular complications of radiotherapy: A role for new pharmacotherapies","volume":"19","author":"Donis","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1667\/RR13979.1","article-title":"Effects of Local Heart Irradiation in a Glutathione S-Transferase Alpha 4-Null Mouse Model","volume":"183","author":"Boerma","year":"2015","journal-title":"Radiat. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00411-016-0643-8","article-title":"Sestrin2 protects the myocardium against radiation-induced damage","volume":"55","author":"Zeng","year":"2016","journal-title":"Radiat. Environ. Biophys."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1667\/RR14403.2","article-title":"IPW-5371 Proves Effective as a Radiation Countermeasure by Mitigating Radiation-Induced Late Effects","volume":"186","author":"Rabender","year":"2016","journal-title":"Radiat. Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gu, A., Jie, Y., Sun, L., Zhao, S., E, M., and You, Q. (2015). RhNRG-1\u03b2 Protects the Myocardium against Irradiation-Induced Damage via the ErbB2-ERK-SIRT1 Signaling Pathway. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137337"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/8\/1007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:10:35Z","timestamp":1760141435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/8\/1007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":123,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ph15081007"],"URL":"https:\/\/doi.org\/10.3390\/ph15081007","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}